Model-based translation of DNA damage signaling dynamics across cell types

PLoS Comput Biol. 2022 Jul 8;18(7):e1010264. doi: 10.1371/journal.pcbi.1010264. eCollection 2022 Jul.

Abstract

Interindividual variability in DNA damage response (DDR) dynamics may evoke differences in susceptibility to cancer. However, pathway dynamics are often studied in cell lines as alternative to primary cells, disregarding variability. To compare DDR dynamics in the cell line HepG2 with primary human hepatocytes (PHHs), we developed a HepG2-based computational model that describes the dynamics of DDR regulator p53 and targets MDM2, p21 and BTG2. We used this model to generate simulations of virtual PHHs and compared the results to those for PHH donor samples. Correlations between baseline p53 and p21 or BTG2 mRNA expression in the absence and presence of DNA damage for HepG2-derived virtual samples matched the moderately positive correlations observed for 50 PHH donor samples, but not the negative correlations between p53 and its inhibitor MDM2. Model parameter manipulation that affected p53 or MDM2 dynamics was not sufficient to accurately explain the negative correlation between these genes. Thus, extrapolation from HepG2 to PHH can be done for some DDR elements, yet our analysis also reveals a knowledge gap within p53 pathway regulation, which makes such extrapolation inaccurate for the regulator MDM2. This illustrates the relevance of studying pathway dynamics in addition to gene expression comparisons to allow reliable translation of cellular responses from cell lines to primary cells. Overall, with our approach we show that dynamical modeling can be used to improve our understanding of the sources of interindividual variability of pathway dynamics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Cyclin-Dependent Kinase Inhibitor p21 / genetics
  • Cyclin-Dependent Kinase Inhibitor p21 / metabolism
  • DNA Damage / genetics
  • Hepatocytes / metabolism
  • Humans
  • Immediate-Early Proteins* / genetics
  • Immediate-Early Proteins* / metabolism
  • Proto-Oncogene Proteins c-mdm2* / genetics
  • Proto-Oncogene Proteins c-mdm2* / metabolism
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Proteins / metabolism

Substances

  • Cyclin-Dependent Kinase Inhibitor p21
  • Immediate-Early Proteins
  • Tumor Suppressor Protein p53
  • Tumor Suppressor Proteins
  • BTG2 protein, human
  • Proto-Oncogene Proteins c-mdm2

Grants and funding

This work has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 681002 (BVDW and JBB) (EU-ToxRisk) and the ZonMW InnoSysTox program under grant agreement No. 40-42600-98-14030.(BVDW and JBB) Moreover, this work has received funding from the TransQST and eTRANSAFE projects, which have both received support from IMI2 Joint Undertaking under Grant Agreements No. 116030(BVDW) and No. 777365(BVDW), respectively. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). This manuscript reflects only the authors' view and IMI JU is not responsible for any use that may be made of the information it contains. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.